Oxnard, CA- FOMAT Medical Research announced today the launch of its new Phase I capabilities. The expansion will enhance FOMAT’s ability to provide efficient and high-quality services to its clients in the pharmaceutical and biotech industries.
The expanded capabilities will include the addition of new state-of-the-art facilities, specialized staff, and innovative technology. FOMAT will now offer a full range of Phase I services, including early-phase clinical trials, pharmacokinetic and pharmacodynamic studies, and first-in-human trials.
The clinic and site-specific processes are designed to carry out simple and complex clinical trials, offered across multiple therapeutic specialties, including infectious diseases, vaccines, CNS, Autoimmune, Inflammation, Metabolic, Endocrinology, NAFLD, NASH, Obesity, T2D clinical trials.
FOMAT Medical Research’s Ealy Phase/Phase One clinic is located just outside of Los Angeles, in Oxnard, California. It features state-of-the art facilities and marks a significant milestone in the company’s service offering, covering all phases of clinical development, and bolsters its ongoing commitment to innovate healthcare through diversity.
About FOMAT Medical Research
FOMAT Medical Research, headquartered in Oxnard, California, is an Integrated Research Organization (IRO), a subset of a Site Management Organization (SMO), focused on innovating healthcare with our high-quality services. With over 10 years of experience in participating in Phase 1 through Phase 4 clinical trials in a wide variety of therapeutic areas, we rely on a highly experienced clinical research team with the professional expertise necessary to assist Sponsors and Contract Research Organizations (CROs) with reaching their project goals quickly and effectively.
If you want more information about our Phase 1 capabilities, please contact:
Business Development Specialist